Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi
 
IRCT20180725040596N2
RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
50/50 inconclusive

    COVID 19 all comers meta-analysis

    Chang Chen et al.
     
    ChiCTR2000030254
    RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
    120/120 inconclusive
    • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).